Analytical Validation and Application of a Targeted Next-Generation Sequencing Mutation-Detection Assay for Use in Treatment Assignment in the NCI-MPACT Trial

Journal of Molecular Diagnostics

Volumn 18, Issue 1, 2016, Pages 51-67

  Lih, Chih Jian ^a   Sims, David J ^a   Harrington, Robin D ^a   Polley, Eric C ^b   Zhao, Yingdong ^b   Mehaffey, Michele G ^a   Forbes, Thomas D ^a   Das, Biswajit ^a   Walsh, William D ^a   Datta, Vivekananda ^a   Harper, Kneshay N ^a   Bouk, Courtney H ^a   Rubinstein, Lawrence V ^b   Simon, Richard M ^b   Conley, Barbara A ^b   Chen, Alice P ^b   Kummar, Shivaani ^b   Doroshow, James H ^b   Williams, Paul M ^a,b  

^a FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ALLYL 1 [6 (1 HYDROXY 1 METHYLETHYL) 2 PYRIDINYL] 6 [4 (4 METHYL 1 PIPERAZINYL)ANILINO] 1H PYRAZOLO[3,4 D]PYRIMIDIN 3(2H) ONE; CARBOPLATIN; DNA; EVEROLIMUS; NUCLEOTIDE; TEMOZOLOMIDE; TRAMETINIB; VELIPARIB;

ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FALSE POSITIVE RESULT; GAIN OF FUNCTION MUTATION; GENE MUTATION; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN; INDEL MUTATION; LOSS OF FUNCTION MUTATION; METASTASIS; NATIONAL HEALTH ORGANIZATION; NEXT GENERATION SEQUENCING; NEXT GENERATION SEQUENCING MUTATION DETECTION ASSAY; PATIENT SELECTION; QUALITY CONTROL; REPRODUCIBILITY; SCREENING; SENSITIVITY AND SPECIFICITY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; VALIDATION PROCESS; DNA SEQUENCE; GENETICS; HIGH THROUGHPUT SEQUENCING; LARGE CORE NEEDLE BIOPSY; MOLECULAR DIAGNOSIS; MUTATION; NEOPLASMS; NUCLEOTIDE SEQUENCE; PILOT STUDY; PLASMID; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; VALIDATION STUDY;

BASE SEQUENCE; BIOPSY, LARGE-CORE NEEDLE; CELL LINE, TUMOR; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASMS; PATIENT SELECTION; PILOT PROJECTS; PLASMIDS; SEQUENCE ANALYSIS, DNA;

EID: 84954055993     PISSN: 15251578     EISSN: 19437811     Source Type: Journal    
DOI: 10.1016/j.jmoldx.2015.07.006     Document Type: Article

References (68)

1. L.E. Macconaill, and L.A. Garraway Clinical implications of the cancer genome J Clin Oncol 28 2010 5219 5228
2. B. Vogelstein, N. Papadopoulos, V.E. Velculescu, S. Zhou, L.A. Diaz Jr., and K.W. Kinzler Cancer genome landscapes Science 339 2013 1546 1558
3. D.G. Savage, and K.H. Antman Imatinib mesylate - a new oral targeted therapy N Engl J Med 346 2002 683 693
4. D.J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, J. Baselga, and L. Norton Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
5. J.A. Sosman, K.B. Kim, L. Schuchter, R. Gonzalez, A.C. Pavlick, J.S. Weber, G.A. McArthur, T.E. Hutson, S.J. Moschos, K.T. Flaherty, P. Hersey, R. Kefford, D. Lawrence, I. Puzanov, K.D. Lewis, R.K. Amaravadi, B. Chmielowski, H.J. Lawrence, Y. Shyr, F. Ye, J. Li, K.B. Nolop, R.J. Lee, A.K. Joe, and A. Ribas Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib N Engl J Med 366 2012 707 714
6. E.L. Kwak, Y.J. Bang, D.R. Camidge, A.T. Shaw, B. Solomon, R.G. Maki, S.H. Ou, B.J. Dezube, P.A. Janne, D.B. Costa, M. Varella-Garcia, W.H. Kim, T.J. Lynch, P. Fidias, H. Stubbs, J.A. Engelman, L.V. Sequist, W. Tan, L. Gandhi, M. Mino-Kenudson, G.C. Wei, S.M. Shreeve, M.J. Ratain, J. Settleman, J.G. Christensen, D.A. Haber, K. Wilner, R. Salgia, G.I. Shapiro, J.W. Clark, and A.J. Iafrate Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
7. The Cancer Genome Atlas Network Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 455 2008 1061 1068
8. The Cancer Genome Atlas Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
9. The Cancer Genome Atlas Network Comprehensive genomic characterization of squamous cell lung cancers Nature 489 2012 519 525
10. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours Nature 490 2012 61 70
11. D. Dias-Santagata, S. Akhavanfard, S.S. David, K. Vernovsky, G. Kuhlmann, S.L. Boisvert, H. Stubbs, U. McDermott, J. Settleman, E.L. Kwak, J.W. Clark, S.J. Isakoff, L.V. Sequist, J.A. Engelman, T.J. Lynch, D.A. Haber, D.N. Louis, L.W. Ellisen, D.R. Borger, and A.J. Iafrate Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine EMBO Mol Med 2 2010 146 158
12. L.E. MacConaill, C.D. Campbell, S.M. Kehoe, A.J. Bass, C. Hatton, L. Niu, M. Davis, K. Yao, M. Hanna, C. Mondal, L. Luongo, C.M. Emery, A.C. Baker, J. Philips, D.J. Goff, M. Fiorentino, M.A. Rubin, K. Polyak, J. Chan, Y. Wang, J.A. Fletcher, S. Santagata, G. Corso, F. Roviello, R. Shivdasani, M.W. Kieran, K.L. Ligon, C.D. Stiles, W.C. Hahn, M.L. Meyerson, and L.A. Garraway Profiling critical cancer gene mutations in clinical tumor samples PLoS One 4 2009 e7887
13. S. Kummar, P.M. Williams, C.J. Lih, E.C. Polley, A.P. Chen, L.V. Rubinstein, Y. Zhao, R.M. Simon, B.A. Conley, and J.H. Doroshow Application of molecular profiling in clinical trials for advanced metastatic cancers (commentary) J Natl Cancer Inst 107 2015 djv003
14. S. Meshinchi, S.P. Hunger, R. Aplenc, P.C. Adamson, and J.M. Jessup Lessons learned from the investigational device exemption review of Children's Oncology Group trial AAML1031 Clin Cancer Res 18 2012 1547 1554
15. R.L. Schilsky, J.H. Doroshow, M. Leblanc, and B.A. Conley Development and use of integral assays in clinical trials Clin Cancer Res 18 2012 1540 1546
16. T. Yamaguchi, R. Kakefuda, N. Tajima, Y. Sowa, and T. Sakai Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo Int J Oncol 39 2011 23 31
17. R.J. Motzer, B. Escudier, S. Oudard, T.E. Hutson, C. Porta, S. Bracarda, V. Grunwald, J.A. Thompson, R.A. Figlin, N. Hollaender, G. Urbanowitz, W.J. Berg, A. Kay, D. Lebwohl, and A. Ravaud Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial Lancet 372 2008 449 456
18. V. Grunwald, P.I. Karakiewicz, S.E. Bavbek, K. Miller, J.P. Machiels, S.H. Lee, J. Larkin, P. Bono, S.Y. Rha, D. Castellano, C.U. Blank, J.J. Knox, R. Hawkins, O. Anak, M. Rosamilia, J. Booth, N. Pirotta, and I. Bodrogi An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy Eur J Cancer 48 2012 324 332
19. J.P. Palma, Y.C. Wang, L.E. Rodriguez, D. Montgomery, P.A. Ellis, G. Bukofzer, A. Niquette, X. Liu, Y. Shi, L. Lasko, G.D. Zhu, T.D. Penning, V.L. Giranda, S.H. Rosenberg, D.J. Frost, and C.K. Donawho ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors Clin Cancer Res 15 2009 7277 7290
20. S. Leijen, J.H. Beijnen, and J.H. Schellens Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents Curr Clin Pharmacol 5 2010 186 191
21. S.A. Forbes, N. Bindal, S. Bamford, C. Cole, C.Y. Kok, D. Beare, M. Jia, R. Shepherd, K. Leung, A. Menzies, J.W. Teague, P.J. Campbell, M.R. Stratton, and P.A. Futreal COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer Nucleic Acids Res 39 2011 D945 D950
22. S.A. Forbes, D. Beare, P. Gunasekaran, K. Leung, N. Bindal, H. Boutselakis, M. Ding, S. Bamford, C. Cole, S. Ward, C.Y. Kok, M. Jia, T. De, J.W. Teague, M.R. Stratton, U. McDermott, and P.J. Campbell COSMIC: exploring the world's knowledge of somatic mutations in human cancer Nucleic Acids Res 43 2015 D805 D811
23. A.G. Gilmartin, M.R. Bleam, A. Groy, K.G. Moss, E.A. Minthorn, S.G. Kulkarni, C.M. Rominger, S. Erskine, K.E. Fisher, J. Yang, F. Zappacosta, R. Annan, D. Sutton, and S.G. Laquerre GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin Cancer Res 17 2011 989 1000
24. D.B. Solit, L.A. Garraway, C.A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J.M. Lobo, Y. She, I. Osman, T.R. Golub, J. Sebolt-Leopold, W.R. Sellers, and N. Rosen BRAF mutation predicts sensitivity to MEK inhibition Nature 439 2006 358 362
25. K.T. Flaherty, J.R. Infante, A. Daud, R. Gonzalez, R.F. Kefford, J. Sosman, O. Hamid, L. Schuchter, J. Cebon, N. Ibrahim, R. Kudchadkar, H.A. Burris 3rd, G. Falchook, A. Algazi, K. Lewis, G.V. Long, I. Puzanov, P. Lebowitz, A. Singh, S. Little, P. Sun, A. Allred, D. Ouellet, K.B. Kim, K. Patel, and J. Weber Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
26. J.H. Mao, I.J. Kim, D. Wu, J. Climent, H.C. Kang, R. DelRosario, and A. Balmain FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression Science 321 2008 1499 1502
27. J.L. Bos ras oncogenes in human cancer: a review Cancer Res 49 1989 4682 4689
28. E.B. Garon, R.S. Finn, W. Hosmer, J. Dering, C. Ginther, S. Adhami, N. Kamranpour, S. Pitts, A. Desai, D. Elashoff, T. French, P. Smith, and D.J. Slamon Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines Mol Cancer Ther 9 2010 1985 1994
29. M. Malumbres, and M. Barbacid RAS oncogenes: the first 30 years Nat Rev Cancer 3 2003 459 465
30. R. Mori, H. Ishiguro, M. Kimura, A. Mitsui, H. Sasaki, K. Tomoda, Y. Mori, R. Ogawa, T. Katada, O. Kawano, K. Harada, Y. Fujii, and Y. Kuwabara PIK3CA mutation status in Japanese esophageal squamous cell carcinoma J Surg Res 145 2008 320 326
31. F. Di Nicolantonio, S. Arena, J. Tabernero, S. Grosso, F. Molinari, T. Macarulla, M. Russo, C. Cancelliere, D. Zecchin, L. Mazzucchelli, T. Sasazuki, S. Shirasawa, M. Geuna, M. Frattini, J. Baselga, M. Gallicchio, S. Biffo, and A. Bardelli Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus J Clin Invest 120 2010 2858 2866
32. K. Yoshikawa, J. Hamada, M. Tada, T. Kameyama, K. Nakagawa, Y. Suzuki, M. Ikawa, N.M. Hassan, Y. Kitagawa, and T. Moriuchi Mutant p53 R248Q but not R248W enhances in vitro invasiveness of human lung cancer NCI-H1299 cells Biomed Res 31 2010 401 411
33. L.R. Dearth, H. Qian, T. Wang, T.E. Baroni, J. Zeng, S.W. Chen, S.Y. Yi, and R.K. Brachmann Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers Carcinogenesis 28 2007 289 298
34. P. Monti, P. Campomenosi, Y. Ciribilli, R. Iannone, A. Aprile, A. Inga, M. Tada, P. Menichini, A. Abbondandolo, and G. Fronza Characterization of the p53 mutants ability to inhibit p73 beta transactivation using a yeast-based functional assay Oncogene 22 2003 5252 5260
35. X.B. Shi, N.J. Nesslinger, A.D. Deitch, P.H. Gumerlock, and R.W. deVere White Complex functions of mutant p53 alleles from human prostate cancer Prostate 51 2002 59 72
36. C. Xue, M. Haber, C. Flemming, G.M. Marshall, R.B. Lock, K.L. MacKenzie, K.V. Gurova, M.D. Norris, and A.V. Gudkov p53 determines multidrug sensitivity of childhood neuroblastoma Cancer Res 67 2007 10351 10360
37. O.N. Aurelio, X.T. Kong, S. Gupta, and E.J. Stanbridge p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines Mol Cell Biol 20 2000 770 778
38. C. Gaiddon, M. Lokshin, J. Ahn, T. Zhang, and C. Prives A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain Mol Cell Biol 21 2001 1874 1887
39. J.Y. Chen, W.D. Funk, W.E. Wright, J.W. Shay, and J.D. Minna Heterogeneity of transcriptional activity of mutant p53 proteins and p53 DNA target sequences Oncogene 8 1993 2159 2166
40. R.K. Brachmann, M. Vidal, and J.D. Boeke Dominant-negative p53 mutations selected in yeast hit cancer hot spots Proc Natl Acad Sci U S A 93 1996 4091 4095
41. P. Monti, P. Campomenosi, Y. Ciribilli, R. Iannone, A. Inga, A. Abbondandolo, M.A. Resnick, and G. Fronza Tumour p53 mutations exhibit promoter selective dominance over wild type p53 Oncogene 21 2002 1641 1648
42. K. Forrester, S.E. Lupold, V.L. Ott, C.H. Chay, V. Band, X.W. Wang, and C.C. Harris Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent Oncogene 10 1995 2103 2111
43. N.M. Hassan, M. Tada, J. Hamada, H. Kashiwazaki, T. Kameyama, R. Akhter, Y. Yamazaki, M. Yano, N. Inoue, and T. Moriuchi Presence of dominant negative mutation of TP53 is a risk of early recurrence in oral cancer Cancer Lett 270 2008 108 119
44. S. Waddell, J.R. Jenkins, and T. Proikas-Cezanne A "no-hybrids" screen for functional antagonizers of human p53 transactivator function: dominant negativity in fission yeast Oncogene 20 2001 6001 6008
45. C.B. Epstein, E.F. Attiyeh, D.A. Hobson, A.L. Silver, J.R. Broach, and A.J. Levine p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors Oncogene 16 1998 2115 2122
46. M.A. Subler, D.W. Martin, and S. Deb Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53 J Virol 68 1994 103 110
47. Y. Zhao, E.C. Polley, M.C. Li, C.J. Lih, A. Palmisano, D.J. Sims, L.V. Rubinstein, B.A. Conley, A.P. Chen, P.M. Williams, S. Kummar, J.H. Doroshow, and R.M. Simon GeneMed: an informatics hub for the coordination of next-generation sequencing studies that support precision oncology clinical trials Cancer Inform 14 2015 45 55
48. P. Cingolani, A. Platts, L. Wang le, M. Coon, T. Nguyen, L. Wang, S.J. Land, X. Lu, and D.M. Ruden A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3 Fly (Austin) 6 2012 80 92
49. R.R. Singh, K.P. Patel, M.J. Routbort, N.G. Reddy, B.A. Barkoh, B. Handal, R. Kanagal-Shamanna, W.O. Greaves, L.J. Medeiros, K.D. Aldape, and R. Luthra Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes J Mol Diagn 15 2013 607 622
50. J.M. Zook, B. Chapman, J. Wang, D. Mittelman, O. Hofmann, W. Hide, and M. Salit Integrating human sequence data sets provides a resource of benchmark SNP and indel genotype calls Nat Biotechnol 32 2014 246 251
51. G. Pont-Kingdon, F. Gedge, W. Wooderchak-Donahue, I. Schrijver, K.E. Weck, J.A. Kant, D. Oglesbee, P. Bayrak-Toydemir, and E. Lyon Design and analytical validation of clinical DNA sequencing assays Arch Pathol Lab Med 136 2012 41 46
52. C.J. Clopper, and E.S. Pearson The use of confidence or fiducial limits illustrated in the case of the binomial Biometrika 26 1934 404 413
53. R Development Core Team R: a language and environment for statistical computing 2014 R Foundation for Statistical Computing Vienna
54. H. Thorvaldsdottir, J.T. Robinson, and J.P. Mesirov Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration Brief Bioinform 14 2013 178 192
55. J.R. Infante, B.G. Somer, J.O. Park, C.P. Li, M.E. Scheulen, S.M. Kasubhai, D.Y. Oh, Y. Liu, S. Redhu, K. Steplewski, and N. Le A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas Eur J Cancer 50 2014 2072 2081
56. G. Bodoky, C. Timcheva, D.R. Spigel, P.J. La Stella, T.E. Ciuleanu, G. Pover, and N.C. Tebbutt A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy Invest New Drugs 30 2012 1216 1223
57. C. Beadling, T.L. Neff, M.C. Heinrich, K. Rhodes, M. Thornton, J. Leamon, M. Andersen, and C.L. Corless Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping J Mol Diagn 15 2013 171 176
58. A.G. Hadd, J. Houghton, A. Choudhary, S. Sah, L. Chen, A.C. Marko, T. Sanford, K. Buddavarapu, J. Krosting, L. Garmire, D. Wylie, R. Shinde, S. Beaudenon, E.K. Alexander, E. Mambo, A.T. Adai, and G.J. Latham Targeted, high-depth, next-generation sequencing of cancer genes in formalin-fixed, paraffin-embedded and fine-needle aspiration tumor specimens J Mol Diagn 15 2013 234 247
59. R. Kanagal-Shamanna, B.P. Portier, R.R. Singh, M.J. Routbort, K.D. Aldape, B.A. Handal, H. Rahimi, N.G. Reddy, B.A. Barkoh, B.M. Mishra, A.V. Paladugu, J.H. Manekia, N. Kalhor, S.R. Chowdhuri, G.A. Staerkel, L.J. Medeiros, R. Luthra, and K.P. Patel Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics Mod Pathol 27 2014 314 327
60. E.H. Shortliffe, R. Davis, S.G. Axline, B.G. Buchanan, C.C. Green, and S.N. Cohen Computer-based consultations in clinical therapeutics: explanation and rule acquisition capabilities of the MYCIN system Comput Biomed Res 8 1975 303 320
61. R.A. Miller, H.E. Pople Jr., and J.D. Myers Internist-1, an experimental computer-based diagnostic consultant for general internal medicine N Engl J Med 307 1982 468 476
62. K.H. Pan, C.J. Lih, and S.N. Cohen Analysis of DNA microarrays using algorithms that employ rule-based expert knowledge Proc Natl Acad Sci U S A 99 2002 2118 2123
63. K.H. Pan, C.J. Lih, and S.N. Cohen Effects of threshold choice on biological conclusions reached during analysis of gene expression by DNA microarrays Proc Natl Acad Sci U S A 102 2005 8961 8965
64. D.D. Von Hoff, J.J. Stephenson Jr., P. Rosen, D.M. Loesch, M.J. Borad, S. Anthony, G. Jameson, S. Brown, N. Cantafio, D.A. Richards, T.R. Fitch, E. Wasserman, C. Fernandez, S. Green, W. Sutherland, M. Bittner, A. Alarcon, D. Mallery, and R. Penny Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers J Clin Oncol 28 2010 4877 4883
65. S. Roychowdhury, M.K. Iyer, D.R. Robinson, R.J. Lonigro, Y.M. Wu, X. Cao, S. Kalyana-Sundaram, L. Sam, O.A. Balbin, M.J. Quist, T. Barrette, J. Everett, J. Siddiqui, L.P. Kunju, N. Navone, J.C. Araujo, P. Troncoso, C.J. Logothetis, J.W. Innis, D.C. Smith, C.D. Lao, S.Y. Kim, J.S. Roberts, S.B. Gruber, K.J. Pienta, M. Talpaz, and A.M. Chinnaiyan Personalized oncology through integrative high-throughput sequencing: a pilot study Sci Transl Med 3 2011 111ra21
66. A. Hollebecque, C. Massard, T. De Baere, N. Auger, L. Lacroix, V. Koubi-Pick, P. Vielh, V. Lazar, R. Bahleda, M. Ngo-camus, E. Angevin, A. Varga, F. Deschamps, A. Gazzah, C. Mazoyer, C. Richon, G. Vassal, A.M. Eggermont, F. Andre, and J.-C. Soria Molecular screening for cancer treatment optimization (MOSCATO 01): a prospective molecular triage trial - interim results (abstract). 2013 ASCO Annual Meeting J Clin Oncol 31 Suppl 2013 2512 Abstract 2512
67. L.M. Bragg, G. Stone, M.K. Butler, P. Hugenholtz, and G.W. Tyson Shining a light on dark sequencing: characterising errors in Ion Torrent PGM data PLoS Comput Biol 9 2013 e1003031
68. L.M. McShane, M.M. Cavenagh, T.G. Lively, D.A. Eberhard, W.L. Bigbee, P.M. Williams, J.P. Mesirov, M.Y. Polley, K.Y. Kim, J.V. Tricoli, J.M. Taylor, D.J. Shuman, R.M. Simon, J.H. Doroshow, and B.A. Conley Criteria for the use of omics-based predictors in clinical trials Nature 502 2013 317 320